Business
Wuhan Updates on Hemp and CBD-Based Products Line
Wuhan Updates on Hemp and CBD-Based Products Line.
About this update from Wuhan General Group (china), Inc.
[{"type":"text","content":"\nBARCELONA, Spain, March 28, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE --  Wuhan General Group (China), Inc. (OTC: WUHN) (the \"Company\" and \"Wuhan\"), announced today that its subsidiary MJ MedTech, Inc. (MJ MedTech) has commenced formulations and prototyping for the Dr. AnnaRx line of hemp and CBD based products.\n The products listed below are being developed in Phase 1 and readied for sale for Q2 2019 onward. These products come under the Cosmetics and Food segments. Cosmetic Day CreamNight CreamFacial CleanserFacial ExfoliatorAnti-AgingShampoo & ConditionerSPF 50+ Sunblock Food CBD Olive OilCBD Salad DressingInfused CoffeeInfused TeaInfused HoneyCBD Chocolate In Phase 2 and 3, the range of products will fall under the Topicals and CAMS (Complementary and Alternative Medicines) segment, respectively. The Company is expected to launch its range of Phase 2 and 3 products to the market in Q4 2019 onward. Topicals CBD Balms for pain and inflammationCBD Ointments for joint careCBD Creams for mind and moodSoft gels CAMS CapsulesSuppositoriesCBD Extracts AntioxidantsImmune BoosterMultivitamins More highlights: The Company forecasts revenues for Q2, Q3 and Q4 2019 of the amount of $585,000, $2,047,500 and $5,265,000, respectively.Wuhan management executives will be visiting South Africa in April to ensure operational performance and conduct product testing by Wuhan's Chief Medical Officer against our quality standards. MJ Medtech will officially relocate the head office to Barcelona, Spain in anticipation of the European launch in 2020 where the Dr. AnnaRx line of hemp and CBD-based products will be sold as well as across South Africa and surrounding countries in more than 1,000 pharmacies in 2019. Wuhan management believes in the transition to the cannabis industry as a strategic move that will ensure future company growth and shareholder value. We are eager to share our vision and success. About Wuhan General Group (China), Inc. Wuhan General Group (China), Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that owns, develops and commercializes a range of CBD-based products. At Wuhan, our mission is to advance CBD-based medicine to the forefront by deploying best practice science and medicine, clinical research and emerging technologies. For further information contac...